Although the IDH mutation (mIDH) is associated with a poor prognosis in some cancers [13], in patients with glioma, it is associated with a higher survival rate when compared with wild type IDH (wtIDH) patients [3,14,15]. The gene discussed is IDH1; the disease is central nervous system cancer.